Skip to main content
Fig. 2 | BMC Health Services Research

Fig. 2

From: Relationships between developmental strategies for additional indications and price revisions for anticancer drugs in Japan

Fig. 2

Kaplan-Meier curve for National Health Insurance price revisions by stratification of drug characteristics. Left panel: Stratified by additional indication, P < 0.001, log-rank test, Median time for an additional indication: 2410 days. Right panel: Stratified by compound type. P < 0.001, log-rank test, Median time for hormonal agent: 3050 days, Median time for cytotoxic drug: 3484 days, Median time for molecularly targeted drug: 3638 days, Median time for immunotherapy drug: 1141 days

Back to article page